Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Distinct Proteasomal Pathways Drive Oncogenic PPM1D Activation.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2026
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Journal: Science translational medicine
Published: May 27, 2026
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma.
Journal: Leukemia
Published: May 09, 2026
Clinicopathologic characterization of plasma cell neoplasms with IGH::CCND3.
Journal: American journal of clinical pathology
Published: April 20, 2026
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial.
Journal: Nature medicine
Published: March 13, 2026
Clinical Impact and Dynamics of Clonal Hematopoiesis with 177Lu-PSMA-617 Therapy in Advanced Prostate Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: January 20, 2026
Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.
Journal: Journal for immunotherapy of cancer
Published: December 12, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 11, 2025
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologists.
Journal: British journal of haematology
Published: November 01, 2025
Mezigdomide for multiple myeloma: a focus on phase 2 trial data.
Journal: Expert opinion on emerging drugs
Published: October 30, 2025
Last Updated: 09/26/2026